



Consumer Health

A Closer Look at Eyewear

Houlihan Lokey Is the Trusted Advisor to More Top Decision-Makers Than Any Other **Independent Global Investment Bank**



| 2,660 | 36 | \$8.3B | \$1.8B | ~25% | NO |
|------------------------|-----------|------------------------------|----------------------------------|-------------------|------|
| GLOBAL EMPLOYEES(1) | LOCATIONS | MARKET CAP ⁽¹⁾ | ANNUAL REVENUE ⁽²⁾ | EMPLOYEE OWNED | DEBT |

Corporate Finance

- No. 1 Global M&A Advisor
- Raised Approximately \$25 Billion in Capital Over the Past Two Years

| 2023 M&A Advisory Ranking All Global Transactions | | | | | |
|--|--------------------|-----|--|--|--|
| Ac | Advisor Deals | | | | |
| 1 | Houlihan Lokey | 352 | | | |
| 2 | Rothschild & Co | 349 | | | |
| 3 | Goldman Sachs & Co | 300 | | | |

Financial Sponsors Coverage

- No. 1 Global Advisor to Private Equity Firms
- 1,000+ Sponsors Covered Globally

| | 022 Most Active Global Investment anks to Private Equity Firms | |
|----|---|-------|
| Ac | lvisor | Deals |
| 1 | Houlihan Lokey | 242 |
| 2 | Lincoln International | 192 |
| | | |

Financial and Valuation Advisory

- No. 1 Global M&A Fairness Opinion Advisor Over the Past 25 Years
- 2,000+ Annual Valuation Engagements

| 1999 to 2023 Global M&A Fairness Advisory Ranking | | | | | |
|--|--------------------------|-----------------------|--|--|--|
| Ac | lvisor | Deals | | | |
| | | | | | |
| 1 | Houlihan Lokey | 1,247 | | | |
| | Houlihan Lokey JP Morgan | 1,247 1,035 | | | |

Financial Restructuring

- No. 1 Global Restructuring Advisor
- \$3.5 Trillion of Aggregate Transaction Value Completed

| | 2023 Global Distressed Debt & Bankruptcy Restructuring Ranking | | | | |
|----|---|-------|--|--|--|
| Ac | lvisor | Deals | | | |
| 1 | Houlihan Lokey | 73 | | | |
| 2 | PJT Partners | 64 | | | |
| 3 | Rothschild | 51 | | | |

Attractiveness of the Eyewear Market: A High-Margin Segment...



...With Strong Sustainable Growth and Structural Tailwinds

Global Eyewear Market

€142B Global Eyewear Market CAGR ('23-'27) €44B European Eyewear CAGR ('23-'27) CAGR ('23-'27)

Macro Trends

2.6B

34%


2020E



4.8B


50%

2050E



Trend to Fashion Eyewear

"Do You Consider Glasses to be Part of Your Personal Style?" (%=Yes)⁽⁴⁾



The Market Is Driven by Attractive Demographic and Health-Related Dynamics...



Demographics

Overall population growth implies an increasing number of people requiring glasses



Healthcare

- Strongly growing share of younger people in need of visual aid due to myopia as a result of exposure to screen displays
- Ageing population requires sight correction with corrective multifocal glasses



Consumer Behaviour

- Consumer individualisation and differentiation driving the trend to:
 - Multiple spectacles, for different occasions (office, sports, etc.)
 - Eyewear as an accessory: from functional/medical aid to lifestyle item



Pricing

- Increasing price transparency and sensitivity of consumers boosted by online availability of information
- Support value-formoney concepts



Positive Impact



Strong Positive Impact



Strong Positive Impact



Positive Impact

...But Still Shows Traits of an Outdated Traditional **Consumer Market**



Still Non-Transparent

Pricing models due to upselling practices of traditional players



Expensive

Due to respective lack of vertical integration



Limited in Brand Awareness


Due to the industry's focus on third-party frames and glasses



"No Fun" Shopping Experience

With most traditional players focusing only on medical aspects and in-store upselling

The Large European Market Offers Significant Consolidation Potential...



...With Five Regions Representing 16% of the Total Global Market

| | Germany | United Kingdom | Italy | Benelux | Nordics |
|------------------------------------|---------------------------|------------------------|------------------------|--|--|
| Market Size | €7.8B | €5.2B | €3.0B | €2.9B | €2.5B |
| Number of Independent Stores | ~9,000 | ~3,600 | ~9,000 | ~2,000 | ~2,100 |
| Market Share Top 3 Chains | 32% | 74% | 8% | Netherlands: 68%Belgium: 13% | Sweden: 65%Denmark: 51% |
| Multifocal (Volume) | ~40% | N/A | ~20% | 30-50% | N/A |
| Reimbursement Scheme | ■ Low/No Reimbursement | ■ Partly Reimbursed | ■ Partly Reimbursed | Netherlands: Low/No ReimbursementBelgium: Partly Reimbursed | Partly Reimbursed |

For Investors, the Market Offers Multiple Growth Opportunities...



...With All Exit Channels—Strategic, Private, and Public **Equity—Feasible**













Private Equity

Organic Growth and Buy-and-Build

Apax.

CVC

















IPO (Initial Public Offering)





WARBY PARKER

IPO Is a Tangible Option, Yet Valuations Have Suffered Recently



WARBY PARKER









Concept

Digitally native omnichannel retailer with a focus on "lifestyle spectacles" increasing store base to generate prescriptive eyewear sales

Fully integrated value-formoney D2C eyewear brand Traditional stationary optical eyewear retailer

Target Group Fashion- and style-oriented, targeting a broad range of customers

Broad range

Fashion- and style-oriented, targeting a broad range of customers


Broad range

Focused on the medical aspect **Practically oriented**

Stores

EV/Sales

>70 (DACH + SE) 260 (US + CA) 542 (SE, FI, NO, DEN)





5.0x 4.5x 4.0x 3.5x 3.0x 2.5x 2.0x 1.5x 1.0x 0.5x Jan-22 Jul-22 Jan-23 Jul-23 Jan-24

valuation Development

5.2x EV/Sales⁽¹⁾ at IPO (First day of trading: 30 June 2021) **vs. 0.3x EV/Sales Today**⁽²⁾

12.6x EV/Sales⁽¹⁾ at IPO (First day of trading: 29 Sept. 2021)⁽³⁾

vs. 2.0x EV/Sales Today(2)

3.5x EV/Sales⁽¹⁾ at IPO (First day of trading: 29 Oct. 2021)

vs. 1.5x EV/Sales Today(2)

Overall, Publicly Listed Optical Eyewear Retailers Trade at ~11x FWD EBITDA...





Historic EV/EBITDA (FY1) Development (L10Y)



...While Historic Transactions Predominantly Traded at 10-11x LTM EBITDA

Historic Transaction Analysis

| Optical Eyewear Retailers | | Optical Eyewear Manufacturers Contact L | | | |
|---------------------------|---------------|---|---------------|-----------|---------------|
| EV/Sales | Median: 1.2x | EV/Sales | Median: 1.3x | EV/Sales | Median: 2.5x |
| EV/EBITDA | Median: 11.0x | EV/EBITDA | Median: 12.6x | EV/EBITDA | Median: 15.6x |

Featured Transactions of the Houlihan Lokey Team


































Tombstones included herein represent transactions closed from 2011 forward. *Selected transactions were executed by Houlihan Lokey professionals while at other firms acquired by Houlihan Lokey or by professionals from a Houlihan Lokey joint venture company.

Houlihan Lokey Team



Consumer, Food, and Retail, Consumer Health

Moritz von Bodman Managing Director +49 (0) 89 413 12 132 Moritz.Bodman@HL.com



Healthcare

Paul Tomasic
Managing Director
Head of European Healthcare
+44 (0) 20 7747 6673
PTomasic@HL.com



Consumer, Food, and Retail, Consumer Health

Jan Niklas Greim-Kuczewski Senior Vice President +49 (0) 89 413 12 140 Jan.Greim-Kuczewski@HL.com

Disclaimer

© 2024 Houlihan Lokey. All rights reserved. This material may not be reproduced in any format by any means or redistributed without the prior written consent of Houlihan Lokey.

Houlihan Lokey is a trade name for Houlihan Lokey, Inc., and its subsidiaries and affiliates, which include the following licensed (or, in the case of Singapore, exempt) entities: in (i) the United States: Houlihan Lokey Capital, Inc., and Houlihan Lokey Advisors, LLC, each an SEC-registered broker-dealer and member of FINRA (www.finra.org) and SIPC (www.sipc.org) (investment banking services); (ii) Europe: Houlihan Lokey Advisory Limited, Houlihan Lokey EMEA, LLP, Houlihan Lokey (Corporate Finance) Limited, and Houlihan Lokey UK Limited, authorized and regulated by the U.K. Financial Conduct Authority; Houlihan Lokey (Europe) GmbH, authorized and regulated by the German Federal Financial Supervisory Authority (Bundesanstalt für Finanzdienstleistungsaufsicht); (iii) the United Arab Emirates, Dubai International Financial Centre (Dubai): Houlihan Lokey (MEA Financial Advisory) Limited, regulated by the Dubai Financial Services Authority for the provision of advising on financial products, arranging deals in investments, and arranging credit and advising on credit to professional clients only; (iv) Singapore: Houlihan Lokey (Singapore) Private Limited and Houlihan Lokey Advisers Singapore Private Limited, each an "exempt corporate finance adviser" able to provide exempt corporate finance advisory services to accredited investors only; (v) Hong Kong SAR: Houlihan Lokey (China) Limited, licensed in Hong Kong by the Securities and Futures Commission to conduct Type 1, 4, and 6 regulated activities to professional investors only; (vi) India: Houlihan Lokey Advisory (India) Private Limited, registered as an investment adviser with the Securities and Exchange Board of India (registration number INA000001217); and (vii) Australia: Houlihan Lokey (Australia) Pty Limited (ABN 74 601 825 227), a company incorporated in Australia and licensed by the Australian Securities and Investments Commission (AFSL number 474953) in respect of financial services provided to wholesale clients only. In the United Kingdom, European Economic Area (EEA), Dubai, Singapore, Hong Kong, India, and Australia, this communication is directed to intended recipients, including actual or potential professional clients (UK, EEA, and Dubai), accredited investors (Singapore), professional investors (Hong Kong), and wholesale clients (Australia), respectively. No entity affiliated with Houlihan Lokey, Inc., provides banking or securities brokerage services and is not subject to FINMA supervision in Switzerland or similar regulatory authorities in other jurisdictions. Other persons, such as retail clients, are NOT the intended recipients of our communications or services and should not act upon this communication.

Houlihan Lokey gathers its data from sources it considers reliable; however, it does not guarantee the accuracy or completeness of the information provided within this presentation. The material presented reflects information known to the authors at the time this presentation was written, and this information is subject to change. Any forward-looking information and statements contained herein are subject to various risks and uncertainties, many of which are difficult to predict, that could cause actual results and developments to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. In addition, past performance should not be taken as an indication or guarantee of future performance, and information contained herein may be subject to variation as a result of currency fluctuations. Houlihan Lokey makes no representations or warranties, expressed or implied, regarding the accuracy of this material. The views expressed in this material accurately reflect the personal views of the authors regarding the subject securities and issuers and do not necessarily coincide with those of Houlihan Lokey. Officers, directors, and partners in the Houlihan Lokey group of companies may have positions in the securities of the companies discussed. This presentation does not constitute advice or a recommendation, offer, or solicitation with respect to the securities of any company discussed herein, is not intended to provide information upon which to base an investment decision, and should not be construed as such. Houlihan Lokey or its affiliates may from time to time provide financial or related services to these companies. Like all Houlihan Lokey employees, the authors of this presentation receive compensation that is affected by overall firm profitability.



CORPORATE FINANCE
FINANCIAL RESTRUCTURING
FINANCIAL AND VALUATION ADVISORY

HL.com